- Home
- NKTR
NKTR
Nektar Therapeutics
as 10-07-2025 3:29pm EST
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.2B | IPO Year: | 1994 |
| Target Price: | $91.67 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.48 - $62.95 | Next Earning Date: | 11-06-2025 |
| Revenue: | $74,934,000 | Revenue Growth: | -19.56% |
| Revenue Growth (this year): | -55.9% | Revenue Growth (next year): | -4.50% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROBIN HOWARD W | NKTR | President & CEO | Sep 9 '25 | Sell | $46.81 | 6,666 | $311,214.24 | 53,908 | |
| ROBIN HOWARD W | NKTR | President & CEO | Sep 5 '25 | Sell | $38.86 | 6,666 | $256,850.84 | 53,908 | |
| ROBIN HOWARD W | NKTR | President & CEO | Sep 4 '25 | Sell | $34.03 | 5,166 | $174,107.75 | 53,908 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Sep 4 '25 | Sell | $34.03 | 1,721 | $57,692.51 | 17,769 | |
| ROBIN HOWARD W | NKTR | President & CEO | Sep 2 '25 | Sell | $30.16 | 1,500 | $45,240.00 | 53,908 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Sep 2 '25 | Sell | $30.10 | 485 | $14,598.50 | 17,769 | |
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Aug 19 '25 | Sell | $26.59 | 676 | $17,974.84 | 20,312 | |
| ROBIN HOWARD W | NKTR | President & CEO | Aug 19 '25 | Sell | $26.59 | 1,573 | $41,826.07 | 53,908 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Aug 19 '25 | Sell | $26.59 | 725 | $19,277.75 | 17,769 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
MT Newswires
15 days ago
B. Riley Boosts Price Target on Nektar Therapeutics to $105 From $85, Keeps Buy Rating
Motley Fool
16 days ago
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Simply Wall St.
18 days ago
How Recent Breakthroughs Are Changing the Nektar Therapeutics Investment Story
Zacks
a month ago
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
Motley Fool
a month ago
Why Nektar Therapeutics Rippled Higher This Week
MT Newswires
a month ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care Stocks Rise Thursday Afternoon
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.